Some leukaemia medicines work by making leukaemia cells mature. This can cause fever, breathlessness, fluid on the lungs, sudden weight gain, swelling, low blood pressure or kidney problems. This is differentiation syndrome. It is treated at once with a steroid such as dexamethasone and can be fatal if not treated. Call your team or go to the nearest emergency department right away.
Differentiation syndrome follows any drug that pushes myeloid blasts to mature: tretinoin and arsenic trioxide in acute promyelocytic leukaemia (APL), the IDH inhibitors ivosidenib, enasidenib and olutasidenib, the FLT3 inhibitor gilteritinib and the menin inhibitors revumenib and ziftomenib. All eight US labels carry a boxed warning. There is no diagnostic test. The PETHEMA criteria (two or more of dyspnoea, unexplained fever, weight gain above 5 kg, unexplained hypotension, acute renal failure, and pulmonary infiltrates or pleuropericardial effusion on imaging) were written for APL and were used by the FDA to re-read the ivosidenib and enasidenib trials, where they found the syndrome in 19% of patients on each drug against 11 to 14% reported, with a median onset of 20 and 19 days and leukocytosis present in 79% and 61% of cases, so not in all.
Timing differs by class. In APL the median onset is 7 to 12 days with two peaks, in the first and third weeks. On IDH inhibitors it can start from day 1 and as late as 3 months (ivosidenib), 5 months (enasidenib) or 18 months (olutasidenib); on gilteritinib from day 1 to day 82; on revumenib a median of 9 days (range 3 to 41); on ziftomenib a median of 15 days (range 3 to 46).
The core of treatment is consistent across the sources: dexamethasone 10 mg every 12 hours started on suspicion (the labels and the ELN APL panel), without waiting for an abnormal chest radiograph (PETHEMA review), with haemodynamic monitoring (the labels). Seven of the eight labels set a minimum of 3 days of steroids; enasidenib's gives no minimum and says to taper only after symptoms resolve, and the ELN panel says steroids can be discontinued once the syndrome has resolved. Hydroxyurea for accompanying leukocytosis is on every label except gilteritinib's, which gives no rule for leukocytosis (the tretinoin label says to consider cytoreductive chemotherapy, including hydroxyurea). Leukapheresis 'if clinically indicated' is on the ivosidenib, revumenib and ziftomenib labels only, and is to be avoided in APL (ELN III-B). The FDA authors say empirical antibiotics are equally important to consider, because infection and the syndrome share signs and can be present together. The sources differ on when to stop the causative drug (at once on olutasidenib, ziftomenib and arsenic trioxide; only if severe signs persist beyond 48 hours of steroids on ivosidenib, gilteritinib and revumenib; only for severe syndrome in the ELN APL recommendations) and on steroid prophylaxis in APL (for adults with newly diagnosed low-risk APL on arsenic trioxide with tretinoin in the US label; optional and of uncertain value, by white count, in the ELN recommendations). The reader's own team's protocol comes first.
Why: Both menin inhibitor labels (revumenib and ziftomenib) give this instruction within their differentiation syndrome warning. Neither states the reason.
“Do not start REVUFORJ until the WBC is reduced to less than 25 Gi/L.”
Syndax Pharmaceuticals (DailyMed, US National Library of Medicine) 2025
Why: The enasidenib label warns that the syndrome can start from 1 day and during the first 5 months of treatment and can be fatal if not treated. Its patient leaflet says to call the team or go to the nearest hospital emergency room right away.
“Ask patients to immediately report any symptoms suggestive of differentiation syndrome, such as fever, cough or difficulty breathing, bone pain, rapid weight gain or swelling of their arms or legs, to their healthcare provider for further evaluation”
Celgene, a Bristol Myers Squibb company (DailyMed, US National Library of Medicine) 2025
Why: The labels record onset as late as 3 months (ivosidenib), 5 months (enasidenib) and 18 months (olutasidenib) after starting, and the FDA authors found repeat episodes in 12% and 15% of patients who had the syndrome.
“It would be prudent to remain vigilant for DS throughout the course of therapy, particularly in patients with active disease and those who resume therapy following treatment interruption.”
Why: There is no diagnostic test. These six signs are the criteria the PETHEMA group used in its large APL series and the FDA used when it re-read the IDH inhibitor trials. No single sign is enough, and other causes of the signs should be ruled out.
“based on the presence of at least two of the following signs and symptoms: dyspnea, unexplained fever, weight gain greater than 5 kg, unexplained hypotension, acute renal failure, and, particularly, a chest radiograph demonstrating pulmonary infiltrates or pleuropericardial effusion.”
Mediterranean Journal of Hematology and Infectious Diseases (Montesinos and Sanz) 2011
Why: Roughly 40 percent of people with the syndrome have a normal chest film at first, and the review says the white count should not be treated as a diagnostic criterion because the syndrome also develops without a rise in it.
“Treatment of DS should not be postponed until after having an abnormal chest radiograph since roughly 40 percent of patients with DS have a normal chest radiograph at presentation.”
Mediterranean Journal of Hematology and Infectious Diseases (Montesinos and Sanz) 2011
Why: The labels say the syndrome can be fatal if not treated. In APL, the PETHEMA review reports that adding chemotherapy early and giving high-dose dexamethasone at the first sign appear to have reduced deaths from the syndrome from 30% to 5% or less in the most recent trials.
“If differentiation syndrome is suspected, initiate dexamethasone 10 mg IV every 12 hours (or an equivalent dose of an alternative oral or IV corticosteroid) and hemodynamic monitoring until improvement.”
Astellas Pharma US (DailyMed, US National Library of Medicine) 2026
Why: The labels list low blood pressure and failure of the lungs, kidneys or several organs among the signs. Every label asks for haemodynamic monitoring; none defines what it consists of, and only the enasidenib label makes the recommendation about admission.
“Hospitalization for close observation and monitoring of patients with pulmonary and/or renal manifestation is recommended.”
Celgene, a Bristol Myers Squibb company (DailyMed, US National Library of Medicine) 2025
Why: The signs overlap with those of infection, the two can be present together, and the FDA authors warn that delaying steroids could be life-threatening or fatal. They word this as something to consider, not as a rule.
“Treatment with empirical antibiotics would be equally important to consider in patients with suspected DS.”
Why: The labels describe the syndrome as associated with rapid proliferation and differentiation of myeloid cells. Their thresholds differ: ivosidenib above 25 x 10^9/L or a rise of more than 15 x 10^9/L from baseline, enasidenib above 30 x 10^9/L, arsenic trioxide above 10 x 10^9/L. The enasidenib, olutasidenib and arsenic trioxide labels name hydroxyurea only, and the gilteritinib label gives no rule for leukocytosis.
“If concomitant noninfectious leukocytosis is observed, initiate treatment with hydroxyurea or leukapheresis, as clinically indicated.”
Servier Pharmaceuticals (DailyMed, US National Library of Medicine) 2025
Why: APL causes a severe bleeding tendency, and the procedure can set off a fatal bleed.
“Leukapheresis should be avoided due to risk of precipitating fatal hemorrhage”
Why: The PETHEMA review calls these supportive measures crucial. In its trials 87% of patients with the syndrome needed diuretics, 26% mechanical ventilation and 12% dialysis.
“In the PETHEMA protocols, furosemide is usually administered to treat acute renal failure, peripheral and pulmonary edema, and weight gain.”
Mediterranean Journal of Hematology and Infectious Diseases (Montesinos and Sanz) 2011
Why: These three labels tell the team to withhold the cause at once and resume it once the person has improved.
“If differentiation syndrome is suspected, interrupt KOMZIFTI, initiate oral or intravenous corticosteroids (e.g., dexamethasone 10 mg every 12 hours) for a minimum of 3 days with hemodynamic and laboratory monitoring.”
Kura Oncology (DailyMed, US National Library of Medicine) 2025
Why: These labels start steroids first and interrupt the drug only if severe signs persist. Enasidenib's label names the severe signs: lung symptoms needing intubation or ventilation, or kidney dysfunction.
“If severe signs and/or symptoms persist for more than 48 hours after initiation of corticosteroids, interrupt TIBSOVO until signs and symptoms are no longer severe”
Servier Pharmaceuticals (DailyMed, US National Library of Medicine) 2025
Why: The panel grades both statements IIa-B. The arsenic trioxide label also says to consider holding tretinoin if symptoms are severe, and the tretinoin label says to consider withholding it for moderate and severe syndrome. The labels and the panel differ, and local protocols follow one or the other.
“Temporary discontinuation of differentiation therapy (ATRA or ATO) is indicated only in case of severe APL differentiation syndrome”
Why: The labels warn that symptoms may recur if steroids, or hydroxyurea, are stopped too soon. The enasidenib label sets no minimum number of days.
“Restart steroids promptly if DS recurs after tapering corticosteroids”
Syndax Pharmaceuticals (DailyMed, US National Library of Medicine) 2025
Why: The labels do not agree on the restart point. Arsenic trioxide resumes at half dose when the clinical condition improves and returns to the recommended dose after one week without recurrence; olutasidenib may resume at a reduced dose after a second episode.
“Resume TIBSOVO when signs and symptoms improve to Grade 2 or lower.”
Servier Pharmaceuticals (DailyMed, US National Library of Medicine) 2025
Why: The enasidenib label sets this schedule, and the ivosidenib label lists leukocytosis and tumour lysis syndrome among the events seen with differentiation syndrome. Other labels set their own monitoring schedules, which are not compared here.
“Assess blood counts and blood chemistries for leukocytosis and tumor lysis syndrome prior to the initiation of IDHIFA and monitor at a minimum of every 2 weeks for at least the first 3 months during treatment.”
Celgene, a Bristol Myers Squibb company (DailyMed, US National Library of Medicine) 2025
How care is usually carried out, read from the guidelines and standards cited. Your own team's protocol and their judgement come first; this page is for understanding it, not for doing it yourself.
Dexamethasone 10 mg every 12 hours started on suspicion is stated by every label read (as the rule or as the example dose) and by the European LeukemiaNet APL recommendations (IIa-B). Every label adds haemodynamic monitoring, and seven of the eight set a minimum of 3 days of steroids (enasidenib's sets none); the ELN panel says only that steroids can be discontinued once the syndrome has resolved. Hydroxyurea for accompanying leukocytosis is on every label except gilteritinib's (the tretinoin label says to consider it). The FDA authors say empirical antibiotics are equally important to consider, and the PETHEMA review says not to wait for an abnormal chest radiograph. The sources differ on two points, and both sides are shown here. First, when to stop the causative drug: at once on suspicion (olutasidenib, ziftomenib and arsenic trioxide labels); only if severe signs persist more than 48 hours after steroids (ivosidenib, gilteritinib and revumenib labels; enasidenib for ventilation or kidney dysfunction beyond 48 hours); 'consider' for moderate and severe syndrome (tretinoin label); only if severe (ELN APL 2019, IIa-B; Brazilian consensus 2024). Second, steroid prophylaxis in APL: prednisone 0.5 mg/kg daily from day 1 to the end of induction for newly diagnosed low-risk APL on arsenic trioxide with tretinoin (US label); 'can be given' (ELN, IV-C), with the ungraded text adding that it can be considered above a white count of 5 to 10 x 10^9/L and that the benefit remains uncertain; used in trials and recommended for all newly diagnosed patients, particularly high-risk (as reported by the MD Anderson review); no prospective evidence, with some protocols using a white count above 5 x 10^3 per microlitre or a creatinine above 1.4 mg/dL (Brazilian consensus). No randomised trial has tested any of these choices.
Servier Pharmaceuticals (DailyMed, US National Library of Medicine) 2025 · Celgene, a Bristol Myers Squibb company (DailyMed, US National Library of Medicine) 2025 · Rigel Pharmaceuticals (DailyMed, US National Library of Medicine) 2025 · Astellas Pharma US (DailyMed, US National Library of Medicine) 2026 · Syndax Pharmaceuticals (DailyMed, US National Library of Medicine) 2025 · Kura Oncology (DailyMed, US National Library of Medicine) 2025 · Par Health USA (DailyMed, US National Library of Medicine) 2026 · Cephalon; adverse reaction contact Teva Pharmaceuticals (DailyMed, US National Library of Medicine) 2026 · Blood (Sanz et al., European LeukemiaNet; several authors declare honoraria or research funding from drug companies including Teva, whose name is on the Trisenox label) 2019 · Hematology, Transfusion and Cell Therapy (de Figueiredo-Pontes et al.; several authors declare speaker or advisory fees from drug companies) 2024 · Blood Cancer Journal (Yilmaz, Kantarjian and Ravandi, MD Anderson Cancer Center) 2021 · Clinical Cancer Research (Norsworthy et al., US Food and Drug Administration; authors report no commercial interests) 2020
Where it differs: The olutasidenib, ziftomenib and arsenic trioxide labels interrupt the drug as soon as the syndrome is suspected, alongside dexamethasone. Ziftomenib resumes at the same dose once signs are grade 2 or lower; arsenic trioxide resumes at half dose when the clinical condition improves and returns to the recommended dose after a week without recurrence; olutasidenib resumes after resolution and may be resumed at a reduced dose if the syndrome recurs.
Evidence: Label rules from single-arm trials. On olutasidenib 19 of 25 patients with the syndrome recovered after treatment or interruption; on ziftomenib treatment was interrupted and resumed in 15 of 112 patients (13%) and stopped for good in 2.
Rigel Pharmaceuticals (DailyMed, US National Library of Medicine) 2025 · Kura Oncology (DailyMed, US National Library of Medicine) 2025 · Cephalon; adverse reaction contact Teva Pharmaceuticals (DailyMed, US National Library of Medicine) 2026
Where it differs: The ivosidenib, gilteritinib and revumenib labels start steroids and keep the drug going, interrupting only if severe signs last more than 48 hours (revumenib: or earlier for life-threatening signs such as needing a ventilator). Enasidenib interrupts for lung symptoms needing intubation or ventilation, or kidney dysfunction, that persist beyond 48 hours. Ivosidenib, enasidenib and gilteritinib resume at grade 2 or lower; revumenib resumes at the same dose at grade 1 or lower.
Evidence: Label rules from single-arm trials. In the FDA's analysis most adjudicated cases were moderate; 6% of cases on ivosidenib and 5% on enasidenib were fatal, and only one of the four fatal cases had been recognised and given steroids.
Servier Pharmaceuticals (DailyMed, US National Library of Medicine) 2025 · Astellas Pharma US (DailyMed, US National Library of Medicine) 2026 · Syndax Pharmaceuticals (DailyMed, US National Library of Medicine) 2025 · Celgene, a Bristol Myers Squibb company (DailyMed, US National Library of Medicine) 2025 · Clinical Cancer Research (Norsworthy et al., US Food and Drug Administration; authors report no commercial interests) 2020
Where it differs: The ELN panel and the Brazilian consensus keep tretinoin and arsenic trioxide going on dexamethasone and stop them only when the syndrome is severe (the Brazilian text: severe respiratory failure, renal failure or admission to intensive care). The tretinoin label says to consider withholding for moderate and severe syndrome. The arsenic trioxide label says to consider holding tretinoin if symptoms are severe. The MD Anderson review says tretinoin with arsenic trioxide should be held in severe syndrome, which it characterises as three or more clinical signs or symptoms. The Brazilian consensus also allows dexamethasone to be raised to 10 mg every 6 hours if there is no improvement after 24 hours.
Evidence: ELN grades this IIa-B. The PETHEMA review calls the question of stopping controversial and notes that in one trial era patients whose tretinoin was stopped for severe syndrome received less tretinoin and relapsed more often, which the authors offer as a possible explanation.
Blood (Sanz et al., European LeukemiaNet; several authors declare honoraria or research funding from drug companies including Teva, whose name is on the Trisenox label) 2019 · Hematology, Transfusion and Cell Therapy (de Figueiredo-Pontes et al.; several authors declare speaker or advisory fees from drug companies) 2024 · Par Health USA (DailyMed, US National Library of Medicine) 2026 · Cephalon; adverse reaction contact Teva Pharmaceuticals (DailyMed, US National Library of Medicine) 2026 · Blood Cancer Journal (Yilmaz, Kantarjian and Ravandi, MD Anderson Cancer Center) 2021 · Mediterranean Journal of Hematology and Infectious Diseases (Montesinos and Sanz) 2011
Where it differs: The US arsenic trioxide label recommends prednisone 0.5 mg/kg daily from day 1 to the end of induction for patients having arsenic trioxide with tretinoin for newly diagnosed low-risk APL. ELN says prophylactic steroids can be given and can be considered when the white count is above 5 to 10 x 10^9/L at presentation or rises after tretinoin starts. The MD Anderson review says prophylactic steroids have been used in prospective trials and recommended for all newly diagnosed patients, particularly those with high-risk disease. The Brazilian consensus notes that some protocols give it for a white count above 5 x 10^3 per microlitre or a creatinine above 1.4 mg/dL.
Evidence: No prospective comparison. Across three PETHEMA trials the incidence of the syndrome was 30% with dexamethasone for a white count above 5 x 10^9/L, 23% with prednisone for all, and 28% with lower-dose dexamethasone for a white count above 5 x 10^9/L; the 2009 PETHEMA paper (abstract) reported a lower incidence of severe syndrome with prednisone for all than with selective dexamethasone, and the review found no reduction in deaths from the syndrome. ELN grades 'can be given' IV-C and states in its text that the value of prophylaxis remains unclear.
Cephalon; adverse reaction contact Teva Pharmaceuticals (DailyMed, US National Library of Medicine) 2026 · Blood (Sanz et al., European LeukemiaNet; several authors declare honoraria or research funding from drug companies including Teva, whose name is on the Trisenox label) 2019 · Blood Cancer Journal (Yilmaz, Kantarjian and Ravandi, MD Anderson Cancer Center) 2021 · Hematology, Transfusion and Cell Therapy (de Figueiredo-Pontes et al.; several authors declare speaker or advisory fees from drug companies) 2024 · Mediterranean Journal of Hematology and Infectious Diseases (Montesinos and Sanz) 2011 · Blood (Montesinos et al., PETHEMA) 2009
Where it differs: On gilteritinib the syndrome can come with a rash or acute febrile neutrophilic dermatosis (painful red skin lumps with fever), which the six PETHEMA criteria do not include.
Evidence: The gilteritinib label lists rash among the findings and notes that some cases had acute febrile neutrophilic dermatosis; the FDA authors suggest a rash criterion may be reasonable for FLT3 inhibitors. Not validated.
Astellas Pharma US (DailyMed, US National Library of Medicine) 2026 · Clinical Cancer Research (Norsworthy et al., US Food and Drug Administration; authors report no commercial interests) 2020
| Recommendation | Grade, as printed | Source |
|---|---|---|
| APL: dexamethasone 10 mg intravenously twice daily at the earliest suspicion; steroids stopped and treatment recommenced once resolved “Corticosteroids (10 mg of dexamethasone IV twice daily) should be started immediately at the earliest clinical suspicion of incipient APL differentiation syndrome; once the syndrome has resolved, steroids can be discontinued and ATO/ATRA recommenced” | IIa–B | Blood (Sanz et al., European LeukemiaNet; several authors declare honoraria or research funding from drug companies including Teva, whose name is on the Trisenox label) 2019 |
| APL: stop tretinoin or arsenic trioxide temporarily only for severe syndrome | IIa–B | Blood (Sanz et al., European LeukemiaNet; several authors declare honoraria or research funding from drug companies including Teva, whose name is on the Trisenox label) 2019 |
| APL: prophylactic corticosteroids are optional “Prophylactic corticosteroids can be given, which may reduce the risk of APL differentiation syndrome” | IV–C | Blood (Sanz et al., European LeukemiaNet; several authors declare honoraria or research funding from drug companies including Teva, whose name is on the Trisenox label) 2019 |
| APL: the value of prophylactic steroids is unclear “Prophylactic corticosteroids to prevent differentiation syndrome have been used in some studies but the value of the use of steroids remains unclear.” | Not graded (text) | Blood (Sanz et al., European LeukemiaNet; several authors declare honoraria or research funding from drug companies including Teva, whose name is on the Trisenox label) 2019 |
| APL: avoid leukapheresis | III–B | Blood (Sanz et al., European LeukemiaNet; several authors declare honoraria or research funding from drug companies including Teva, whose name is on the Trisenox label) 2019 |
| APL: hydroxyurea 2 g a day, or idarubicin or gemtuzumab ozogamicin for extreme counts, can be considered when the white count rises after tretinoin or arsenic starts | IV–C | Blood (Sanz et al., European LeukemiaNet; several authors declare honoraria or research funding from drug companies including Teva, whose name is on the Trisenox label) 2019 |
| APL on arsenic trioxide with tretinoin: prednisone prophylaxis for all from day 1 to the end of induction “Differentiation syndrome prophylaxis consisting of prednisone 0.5 mg/kg daily from day 1 until the end of induction cycle with TRISENOX and tretinoin is recommended.” | Regulatory label; not graded | Cephalon; adverse reaction contact Teva Pharmaceuticals (DailyMed, US National Library of Medicine) 2026 |
| Arsenic trioxide: withhold on suspicion, dexamethasone 10 mg intravenously every 12 hours for at least 3 days “If differentiation syndrome is suspected, temporarily withhold TRISENOX and immediately initiate dexamethasone 10 mg intravenously every 12 hours and hemodynamic monitoring until resolution of signs and symptoms for a minimum of 3 days” | Regulatory label; not graded | Cephalon; adverse reaction contact Teva Pharmaceuticals (DailyMed, US National Library of Medicine) 2026 |
| Tretinoin: dexamethasone until signs have abated for at least 3 days; consider withholding for moderate and severe syndrome “Consider withholding tretinoin capsules for moderate and severe differentiation syndrome until resolution” | Regulatory label; not graded | Par Health USA (DailyMed, US National Library of Medicine) 2026 |
| Olutasidenib: withhold on suspicion and give steroids for at least 3 days and until resolution “If differentiation syndrome is suspected, temporarily withhold REZLIDHIA and initiate systemic corticosteroids (e.g., dexamethasone 10 mg IV every 12 hours) for a minimum of 3 days and until resolution of signs and symptoms.” | Regulatory label; not graded | Rigel Pharmaceuticals (DailyMed, US National Library of Medicine) 2025 |
| Enasidenib: interrupt for lung symptoms needing ventilation, or kidney dysfunction, lasting more than 48 hours after steroids “If severe pulmonary symptoms requiring intubation or ventilator support, and/or renal dysfunction persist for more than 48 hours after initiation of corticosteroids, interrupt IDHIFA until signs and symptoms are no longer severe” | Regulatory label; not graded | Celgene, a Bristol Myers Squibb company (DailyMed, US National Library of Medicine) 2025 |
| Revumenib: interrupt if severe signs persist beyond 48 hours of steroids, or earlier if life-threatening “Interrupt REVUFORJ if severe signs and/or symptoms persist for more than 48 hours after initiation of systemic corticosteroids, or earlier if life-threatening symptoms occur such as pulmonary symptoms requiring ventilator support.” | Regulatory label; not graded | Syndax Pharmaceuticals (DailyMed, US National Library of Medicine) 2025 |
| APL: steroid prophylaxis has no prospective evidence “Steroids are used to prevent DS, but there is no prospective evaluation of this benefit.” | Not graded (consensus text) | Hematology, Transfusion and Cell Therapy (de Figueiredo-Pontes et al.; several authors declare speaker or advisory fees from drug companies) 2024 |
| IDH inhibitors: the syndrome occurred in 19% of patients on each drug when standard criteria were applied “Both ivosidenib and enasidenib caused DS in 19% of patients, and grade ≥ 3 ARs were present in over half of cases; rare fatalities were observed.” | FDA pooled analysis of two single-arm trials; not graded | Clinical Cancer Research (Norsworthy et al., US Food and Drug Administration; authors report no commercial interests) 2020 |
Shares Tumour lysis syndrome: risk assessment, prophylaxis and treatment, Hyperleukocytosis and leukostasis in acute leukaemia: supportive care, cytoreduction and leukapheresis, Tumour lysis syndrome (TLS).
Shares Olutasidenib, Enasidenib, Ivosidenib.
Shares Hydroxyurea (hydroxycarbamide), Tumour lysis syndrome (TLS).
Shares Tretinoin (all-trans retinoic acid, ATRA), Arsenic trioxide.
Shares Tumour lysis syndrome: risk assessment, prophylaxis and treatment, Tumour lysis syndrome (TLS).
Shares Tretinoin (all-trans retinoic acid, ATRA), Arsenic trioxide.
Shares Tretinoin (all-trans retinoic acid, ATRA), Arsenic trioxide.
Shares Olutasidenib, Enasidenib, Differentiation syndrome, Ivosidenib.